Synapse - Department of Medicine

Results (39595)

Longer-term safety and efficacy of selinexor maintenance therapy for patients with TP53wt advanced or recurrent endometrial cancer: Follow-up subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO Study

Meeting Abstract

Valabrega, G.; Vergote, I.; Richardson, D.; Pérez-Fidalgo, A.; Van Gorp, T.; Sehouli, J.; Weinberger, V.; Bruchim, I.; Oza, A.; Spitz, D. L.; more...
International Journal of Gynecological Cancer (2025)

Fulltext@MSK | Save

Autologous patch healing vs secondary intention healing after Mohs micrographic surgery - A randomized controlled trial

Meeting Abstract

Hjorth, M. K.; Burian, E. A.; Karlsmark, T.; Mogensen, M.; Glud, M.; Harager, A. A.; Rossi, A.; Karmisholt, K.
Acta Dermato-Venereologica (2025)

Fulltext@MSK | Save

Opportunities for home cancer care: The final frontier

Editorial

Doshi, S. D.; Malling, C. D.; McNiff Landrum, K.; Zachariah, F.; Bange, E. M.; Daly, B.
NEJM Catalyst Innovations in Care Delivery (2025)

Fulltext@MSK | Save

Beamion PANTUMOR-1: A phase II, multicenter, multicohort, open-label trial to evaluate the efficacy and safety of the oral HER2-selective tyrosine kinase inhibitor zongertinib for the treatment of HER2 -mutated or overexpressed/amplified solid tumors

Meeting Abstract

Schram, A. M.; Clay, T. D.; Prenen, H.; Park, J. J.; Lunger, L.; Hussain, J.; Maier, D.; Kitano, S.; Dumbrava, E. E.; Kim, H. D.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

RYZ101 ((225)Ac-DOTATATE) in patients with estrogen receptor-positive, human epidermal growth factor receptor 2–negative, locally advanced and unresectable, or metastatic breast cancer progressing after prior therapy: The phase 1b/2 TRACY-1 study

Meeting Abstract

Mayer, E. L.; Miller, K.; Jhaveri, K. L.; Yeh, R.; Sakach, E.; Prasad, V.; Ferreira, D. V.; Herszdorfer, P.; Gong, L.; Li, J.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

A phase 1/2 study of FOG-001, a first-in-class direct β-catenin: TCF inhibitor, in patients with colorectal cancer (CRC) and other locally advanced or metastatic solid tumors

Meeting Abstract

Papadopoulos, K. P.; Cecchini, M.; Khushman, M. M.; Pelster, M.; Rodon Ahnert, J.; Kummar, S.; Yaeger, R.; Sharma, S.; Wells, A.; Garofalo, A.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Cutaneous toxicity and clinical outcomes with enfortumab vedotin and pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma

Meeting Abstract

Arbuiso, A.; Sternschuss, M.; Whiting, K.; Gupta, A.; Huttenlocher Bent, E.; Alvarez, N.; Regazzi, A. M.; Liang, S.; Ahmed, F.; Akin, O.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Study EV-103 cohort H: Neoadjuvant treatment with enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) with muscle invasive bladder cancer (MIBC)—3-year efficacy results

Meeting Abstract

Mar, N.; Petrylak, D. P.; Hoimes, C. J.; Rosenberg, J. E.; Flaig, T. W.; Gourdin, T. S.; Barata, P. C.; Henry, E.; Bilen, M. S.; George, S.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

MRI radiomics to predict outcome of neoadjuvant chemotherapy in patients with muscle invasive bladder cancer undergoing radical cystectomy

Meeting Abstract

Schwartz, L. H.; Akin, O.; Gold, S.; Deng, Y.; Lema-Dopico, A.; Chahwan, S.; Nincevic, J.; Ruby, L.; Capanu, M.; Apte, A.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Impact of MTAP deletion on immunotherapy outcomes in patients with mesothelioma

Meeting Abstract

Ross, J.; Ortiz, E.; Barraza, G.; Mayoral, M.; Ginsberg, M. S.; Luongo, A.; Arfe, A.; Zauderer, M. G.; Adusumilli, P. S.; Eckert, S.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save